Imricor Medical Systems Inc (ASX: IMR) Share Price and News
Price
$1.695
Movement
0.005 (-0.29%)
as at 12 May - Closed (20 mins delayed)
52 Week Range
$0.41 - $1.855
1 Year Return
+272.53%
Imricor Medical Systems Inc Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.Share Price
$1.695
Day Change
0.005 (-0.29%)
52 Week Range
$0.41 - $1.855
Yesterday's Close
$1.70
Today's Open
$1.72
Days Range
$1.62 - $1.72
Volume
189,463
Avg. Volume (1 month)
415,024
Turnover
$318,233
as at 12 May - Closed
Imricor Medical Systems Inc (ASX: IMR)
Latest News

Share Fallers
Why Imricor, Nanosonics, Perpetual, and Tourism Holdings shares are sinking today

Share Market News
Why Antipa, Imricor, Lynas, and Newmont shares are pushing higher today

Healthcare Shares
Up 200% in a year! Why is this ASX healthcare stock rocketing today?

Share Gainers
Why Brainchip, Imricor, Strike Energy, and Wildcat shares are rising today

Share Gainers
Why Imricor, Maas, Resolute Mining, and Select Harvests shares are charging higher

Share Gainers
Why DroneShield, Imricor, IAG, and Sayona Mining shares are roaring higher

Share Market News
ASX healthcare stock rockets 25% on big AI news

Healthcare Shares
Here's why the Imricor Medical (ASX:IMR) share price is surging 8% today

Healthcare Shares
Imricor Medical (ASX:IMR) share price spikes 6% after expanding trial sites

Share Market News
Why the Imricor (ASX:IMR) share price is racing 6% higher today

Healthcare Shares
Imricor (ASX:IMR) share price rises on latest update

Share Market News
Why the Imricor (ASX:IMR) share price is edging higher today
IMR ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
---|---|---|---|---|---|
5th May 2025 2025-05-05T16:57:47 | Release from Voluntary Escrow | YesNo | 4:57pm | 2 | 230k |
1st May 2025 2025-05-01T08:58:35 | Procedures Commence at Semmelweis University | YesNo | 8:58am | 2 | 238k |
23rd Apr 2025 2025-04-23T10:19:46 | Imricor Q1 CY25 Quarterly Activities Report and Appendix 4C | YesNo | 10:19am | 10 | 702k |
17th Apr 2025 2025-04-17T08:53:58 | CE Mark Approval for Advantage-MR under EU's MDR | YesNo | 8:53am | 2 | 241k |
16th Apr 2025 2025-04-16T16:49:04 | Change in substantial holding from CGF | YesNo | 4:49pm | 6 | 334k |
16th Apr 2025 2025-04-16T16:20:19 | Change in substantial holding | YesNo | 4:20pm | 4 | 251k |
14th Apr 2025 2025-04-14T11:15:14 | Notification regarding unquoted securities - IMR | YesNo | 11:15am | 6 | 16k |
11th Apr 2025 2025-04-11T08:40:20 | Imricor Commences VISABL-VT Clinical Trial | YesNo | 8:40am | 2 | 239k |
10th Apr 2025 2025-04-10T16:53:21 | Notice of Annual Stockholders Meeting and CDI Voting Form | YesNo | 4:53pm | 39 | 1.2M |
10th Apr 2025 2025-04-10T16:47:46 | Appendix 4G and Corporate Governance Statement | YesNo | 4:47pm | 24 | 521k |
About Imricor Medical Systems Inc
Imricor Medical Systems Inc is a medical device company that develops MRI-guided technology to address issues with traditional X-ray ablation procedures. Its principal business activities are designing, manufacturing, and selling MRI-compatible products for cardiac catheter ablation procedures to treat arrhythmias. The company's products include the Advantage-MR EP Recorder/Stimulator, Vision-MR Ablation Catheter, and Vision-MR Dispersive Electrode. Geographically, the company generates maximum revenue from Europe, followed by the Middle East and the United States.
IMR Share Price History Data provided by Morningstar.
Date | Close | Change | % Change | Volume | Open | High | Low |
---|---|---|---|---|---|---|---|
09 May 2025 | $1.70 | $-0.08 | -4.51% | 182,890 | $1.83 | $1.83 | $1.70 |
08 May 2025 | $1.78 | $0.08 | 4.71% | 403,610 | $1.73 | $1.84 | $1.72 |
07 May 2025 | $1.70 | $0.00 | 0.00% | 487,030 | $1.70 | $1.71 | $1.68 |
06 May 2025 | $1.70 | $-0.04 | -2.30% | 491,695 | $1.73 | $1.75 | $1.66 |
05 May 2025 | $1.74 | $-0.02 | -1.13% | 726,647 | $1.82 | $1.86 | $1.68 |
02 May 2025 | $1.77 | $0.08 | 4.75% | 313,285 | $1.66 | $1.80 | $1.63 |
01 May 2025 | $1.69 | $0.07 | 4.32% | 191,764 | $1.69 | $1.71 | $1.61 |
30 Apr 2025 | $1.62 | $0.00 | 0.00% | 540,708 | $1.64 | $1.71 | $1.61 |
29 Apr 2025 | $1.63 | $0.04 | 2.52% | 134,938 | $1.59 | $1.63 | $1.56 |
28 Apr 2025 | $1.59 | $-0.02 | -1.25% | 619,963 | $1.60 | $1.60 | $1.49 |
24 Apr 2025 | $1.61 | $0.10 | 6.62% | 387,090 | $1.52 | $1.65 | $1.51 |
23 Apr 2025 | $1.51 | $0.11 | 7.86% | 494,661 | $1.42 | $1.52 | $1.42 |
22 Apr 2025 | $1.40 | $-0.07 | -4.76% | 413,281 | $1.45 | $1.46 | $1.38 |
17 Apr 2025 | $1.47 | $0.01 | 0.69% | 501,587 | $1.46 | $1.47 | $1.37 |
16 Apr 2025 | $1.46 | $-0.01 | -0.68% | 232,610 | $1.51 | $1.51 | $1.42 |
15 Apr 2025 | $1.47 | $0.06 | 4.26% | 509,853 | $1.43 | $1.48 | $1.38 |
14 Apr 2025 | $1.41 | $-0.06 | -4.08% | 423,789 | $1.55 | $1.55 | $1.40 |
Director Transactions Data provided by Morningstar.
Date | Director | Type | Amount | Value | Notes |
---|---|---|---|---|---|
06 Jun 2024 | Steve Wedan | Issued | 2,113,342 | $951,003 |
Issue of options.
|
22 May 2024 | Steve Wedan | Buy | 100,000 | $45,000 |
Off-market trade. CDIs
|
21 May 2024 | Peter McGregor | Issued | 107,556 | $47,862 |
Issue of securities. CDI
|
21 May 2024 | Mark Tibbles | Issued | 107,556 | $47,862 |
Issue of securities. CDIs
|
21 May 2024 | Anita Messal | Issued | 100,834 | $44,871 |
Issue of securities.
|
Directors & Management Data provided by Morningstar.
Name | Title | Start Date | Profile |
---|---|---|---|
Mr Peter McGregor | Non-Executive Director | May 2019 |
Mr McGregor has over 30 years of experience in senior finance and management roles, including having been a partner in the investment banking firm of Goldman Sachs JBWere and a managing director in the institutional banking & markets division of Commonwealth Bank of Australia. Mr McGregor is an experienced company director, and currently serves as a Director of Treasury Corporation of Victoria and Green Eco International Limited, and is a former director of TRUE Infrastructure Management Pty Ltd, and the Brisbane Lions Australian Football Club. He is chair of the Risk Committee.
|
Mr Steve Wedan | Chief Executive OfficerPresidentExecutive ChairmanExecutive Director | May 2006 |
Mr Wedan has over 30 years of experience in the medical device industry including design engineering of MRI and ultrasound systems for GE Healthcare, as well as Vice President and Chief Technology Officer for Applied Biometrics Inc. Immediately prior to co-founding Imricor, Mr Wedan founded and operated a technical consulting company, Wedan Technologies Inc., from 2000-2006. Mr Wedan is a member of international standards committees in the fields of MRI safety and the compatibility of implanted and interventional products in MRI. Mr Wedan currently serves on the Board of Directors of Medical Device Research Forum, Inc. and Water Rescue Innovations, Inc., as well as the Advisory Board of Poiesis Medical, LLC.
|
Mr Mark Tibbles | Non-Executive Deputy ChairmanNon-Executive Director | Sep 2014 |
Mr Tibbles is an entrepreneur, business owner, company director and active venture investor in and advisor to technology, life science and medical device companies. Mr Tibbles is currently a Board member of FamGenix, and CorVent Medical, Inc.; Co-Founder and Board member of PERMnet, Inc.; an owner and managing member of STEM Fuse, LLC, one of the providers of digital K-12 STEM curriculum in the U.S.; and the Managing Director of Strategic Stage Ventures, LLC. Prior to his current roles, Mr Tibbles was a Board member of the Nerdery, LLC as well as an owner and member of Intuitive Technology Group until it was sold in 2017. Mr Tibbles was also a President and founder of PRC Consulting, Inc., a company in the management and implementation of IT projects for Fortune 1000 Companies, from 1998 until 2013, when PRC was sold. He is member of the Risk Committee.
|
Ms Anita Messal | Non-Executive Director | Mar 2021 |
Ms Messal is an executive with 40 years of accomplishments across a variety of functions. With a career in healthcare and benefits, she has experience in health plan services, health care delivery, care management, and benefits administration. Ms Messal has experience in public, private, and non-profit sectors, working in both domestic and international markets. She has led areas of company performance, including sales, product, operations, and technology. Her responsibilities have encompassed M&A integration, data exchange, account management, customer service, system development, information security, product development, national accounts, project management, vendor management, strategic systems, legal, human resources, and learning & development. Ms Messal has also played a role in fundraising from start-up through IPO and sale to strategic buyers and private equity. Ms Messal currently serves on the Board of Directors of Ideon as Executive Chair and is an Advisor to Poiesis Medical. She is member of the Risk Committee.
|
Mr Jeffrey Leighton | Non-Executive Director | Jul 2024 |
Dr Leighton is a cognitive neuroscientist with experience in both academic and corporate settings. He has a robust research, teaching, and leadership background. Dr Leighton has business acumen as CFO at NDS Wellness, a regional (23 states) provider of mobile neuroimaging and wellness centers. He was in the company's growth phase, managing financial operations and working with the CEO. NDS Wellness offered comprehensive services, including mobile wellness clinics, telehealth, and health screenings, to corporations and self-insured companies. Dr Leighton has held key corporate governance and advisory roles, including serving as an Institutional Review Board (IRB) member at a non-profit neuromodulatory research center.
|
Mr Kobe Li | Company Secretary |
-
|
|
Gregg Stenzel | Chief Operating Officer |
-
|
|
Kobe Li | Company Secretary |
-
|
|
Nick Corkill | Vice President Corporate Strategy |
-
|
|
Kate Lindborg | Vice President of Clinical Affairs |
-
|
|
Jonathon Gut | Vice President of Finance and Chief Financial Officer |
-
|
|
Greg Englehardt | Vice President of Global Sales |
-
|
|
Nick Twohy | Vice President of Marketing and Business Development |
-
|
|
Vic Fabano | Vice President of Operations |
-
|
|
Jennifer Weisz | Vice President of Regulatory and Quality |
-
|
Top Shareholders Data provided by Morningstar.
Name | Shares | Capital |
---|---|---|
Citicorp Nominees Pty Limited <Domestic Hin A/C> | 56,359,497 | 17.59% |
HSBC Custody Nominees (Australia) Limited | 44,330,815 | 13.84% |
BNP Paribas Noms (Nz) Ltd | 17,075,876 | 5.33% |
J P Morgan Nominees Australia Pty Limited | 15,569,712 | 4.86% |
Argo Investments Limited | 11,238,407 | 3.51% |
Warren G Herreid Ii | 9,486,098 | 2.96% |
Siemens Medical Solutions Usa Inc | 8,384,150 | 2.62% |
UBS Nominees Pty Ltd | 7,742,928 | 2.42% |
BNP Paribas Nominees Pty Ltd <Ib Au Noms Retailclient> | 7,409,555 | 2.31% |
HR Global Investments Llc | 6,879,579 | 2.15% |
HSBC Custody Nominees (Australia) Limited A/C 2 | 5,680,400 | 1.77% |
Kahr Foundation | 2,950,988 | 0.92% |
Mr Grant Bruce Byron Taylor and Mr Keith Robert Taylor <Sorrento A/C> | 2,732,000 | 0.85% |
Steven R Wedan | 2,693,720 | 0.84% |
Maclay Group Pty Ltd <Maclay Longhurst Family A/C> | 2,662,178 | 0.83% |
Mr Kenneth Joseph Hall <Hall Park A/C> | 1,923,077 | 0.60% |
Pounamu Capital Pty Limited | 1,923,077 | 0.60% |
BNP Paribas Noms Pty Ltd | 1,862,834 | 0.58% |
Merrill Lynch (Australia) Nominees Pty Limited | 1,813,512 | 0.57% |
Bauer Private Equity Fund Vi Llc | 1,696,555 | 0.53% |